As the third wave of modern pharmaceuticals arrives, small nucleic acid drugs are no longer just a vision in the lab — they have become the main battleground for global industrial competition.

From rare diseases to major chronic indications, from "once-every-six-months" long-acting dosing to breakthrough extrahepatic delivery — in 2026, small nucleic acid therapeutics are experiencing a full-scale explosion, evolving from 1 to 100.

Looking across the globe, multinational giants, emerging biotechs, and traditional pharmaceutical companies are all making heavy moves into the space — whether through multi-billion dollar acquisitions, building in-house platforms, or forging deep collaborations — actively riding this "third wave of modern pharmaceuticals." The small nucleic acid track has become a contested territory that no player can afford to ignore.

From nucleotide synthesis to chemical modification, from non-clinical evaluation to commercial manufacturing, a complete industrial infrastructure is rapidly taking shape on a global scale. This is no longer a single-country narrative — it is a global, co-evolving industrial transformation!

Small Nucleic Acid Drug Innovation Global Conference Session — co-organized by Tofflon Group, InnoStar, ChemPartner, and GemPharmatech — today announces its first group of speakers. Leading scientists, pharma executives, and clinical experts from China and abroad will gather on the same stage for conversations focused not on rhetoric, but on breakthroughs, collaboration, and the future.

Standing at the crest of this wave, with a global perspective, we are forging a great power vision. July 22–24, Shanghai National Exhibition and Convention Center —CPIC 2026 invites you to ride the tide and help define the next decade.

Speaker List

Co-organizers: Tofflon Group, InnoStar, ChemPartner, GemPharmatech

Session Dates: Full day, July 23 – Morning, July 24

Session Curators:
Liang Zicai: Chairman & CEO, Ribo Life Science
Chang Yan: President, InnoStar
Li Hao: CMO, Pharmaron

Speakers:

Chang Nannan: Managing Director, Hillhouse Ventures
Gan Quan: Managing Director, CMC Capital
Huang Yi: General Manager, Innovative Drug Division, Chengdu Gowell Biopharmaceutical Co., Ltd.
Huang Yuanyu: Founder, Rigerna
Ji Qunsheng: Co-Founder, CEO & Executive Director, Gemrison Therapeutics
Li Longcheng: Founder & CEO, Ractigen Therapeutics
Li Qian: Chairman, Sun-Novo Pharmaceuticals
Liu Xinxing: General Manager, Shanghai Refreshgene Technology Co., Ltd.
John Taylor: CBO, Ribo Life Science
Qi Fei: Executive Director, Legend Capital
Qi Xinming: Professor, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Shen Dong: Founder & President, LaNova Medicines
Shu Dongxu: Co-Founder, Chairman & CEO, Argo Biopharma
Su Xiaoye: Dean, Nucleic Acid Drug Institute, CSPC Pharmaceutical Group
Tian Weiwei: VP of R&D & General Manager China, Sirnaomics
Wan Jinqiao: Chairman & General Manager, Leaderna Therapeutics Ltd.
Wang Haisheng: Founder & CEO, SicaGene
Wang Lijuan: CSO, Shenzhen Salubris Pharmaceuticals
Wang Li: Member, Investment Banking Committee, Guotai Haotong Securities
Xie Dong: Chairman & Chief Scientist, Frontier Biotech
Zhang Lianshan: Director & Executive Vice President, Jiangsu Hengrui Pharmaceuticals
Zhao Chengjiang: Co-Founder, CTO & Dean, Nucleic Acid Drug Institute, Youjia Bio
Zhao Chunlin: Founder, Anlong Bio
Zhu Yun: CEO, Yunho Bio
Zou Xiaoming: CEO, Visirna Therapeutics
DONG-KI LEE: CEO, Olix Pharmaceuticals